Mepolizumab and exacerbations of refractory eosinophilic asthma.
BACKGROUND: Exacerbations of asthma are associated with substantial morbidity and mortality and with considerable use of health care resources. Preventing exacerbations remains an important goal of therapy. There is evidence that eosinophilic inflammation of the airway is associated with the risk of...
Main Authors: | Haldar, P, Brightling, C, Hargadon, B, Gupta, S, Monteiro, W, Sousa, A, Marshall, R, Bradding, P, Green, R, Wardlaw, A, Pavord, I |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2009
|
Similar Items
-
Mepolizumab in refractory eosinophilic asthma.
by: Pavord, I, et al.
Published: (2010) -
Exacerbations of severe asthma in patients treated with mepolizumab
by: Shrimanker, R, et al.
Published: (2018) -
Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
by: Shrimanker, R, et al.
Published: (2017) -
Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis
by: Haldar, P, et al.
Published: (2014) -
Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis
by: Haldar, P, et al.
Published: (2014)